LYEL
Lyell Immunopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$320.14M
P/E Ratio
—
EPS
$-13.62
Beta
-0.09
52W High
$45.00
52W Low
$8.46
50-Day MA
$19.38
200-Day MA
$20.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Fundamentals
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | 31,000 |
| EBITDA | $-176.04M |
| Operating Margin | -2213050.00% |
| Return on Equity | -80.80% |
| Return on Assets | -29.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.73 |
| Price-to-Book | 1.17 |
| Price-to-Sales (TTM) | 10327.22 |
| EV/Revenue | 3406.7 |
| EV/EBITDA | 0.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -71.40% |
| Shares Outstanding | $23.33M |
| Float | $10.39M |
| % Insiders | 35.41% |
| % Institutions | 58.33% |
Historical Volatility
HV 10-Day
125.67%
HV 20-Day
101.37%
HV 30-Day
85.80%
HV 60-Day
77.14%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($37.17 target)
2
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026